NUTEX HEALTH INC (NUTX) Stock Fundamental Analysis
NASDAQ:NUTX - Nasdaq - US67079U3068 - Common Stock - Currency: USD
NUTX gets a fundamental rating of 6 out of 10. The analysis compared the fundamentals against 103 industry peers in the Health Care Providers & Services industry. Both the profitability and the financial health of NUTX get a neutral evaluation. Nothing too spectacular is happening here. NUTX has both an excellent growth and valuation score. This means it is growing and it is still cheap. This is a rare combination! These ratings could make NUTX a good candidate for value and growth investing.
1. Profitability
1.1 Basic Checks
NUTX had positive earnings in the past year.
NUTX had a positive operating cash flow in the past year.
In the past 5 years NUTX reported 4 times negative net income.
The reported operating cash flow has been mixed in the past 5 years: NUTX reported negative operating cash flow in multiple years.
1.2 Ratios
NUTX's Return On Assets of 8.82% is amongst the best of the industry. NUTX outperforms 92.23% of its industry peers.
With an excellent Return On Equity value of 34.08%, NUTX belongs to the best of the industry, outperforming 95.15% of the companies in the same industry.
The Return On Invested Capital of NUTX (30.54%) is better than 99.03% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 8.82% | ||
| ROE | 34.08% | ||
| ROIC | 30.54% |
ROA(3y)-33.97%
ROA(5y)-688.28%
ROE(3y)-160.63%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
With an excellent Profit Margin value of 10.76%, NUTX belongs to the best of the industry, outperforming 96.12% of the companies in the same industry.
The Operating Margin of NUTX (33.39%) is better than 99.03% of its industry peers.
With a decent Gross Margin value of 48.77%, NUTX is doing good in the industry, outperforming 74.76% of the companies in the same industry.
NUTX's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 33.39% | ||
| PM (TTM) | 10.76% | ||
| GM | 48.77% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y22.83%
GM growth 5Y0.83%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so NUTX is creating value.
Compared to 1 year ago, NUTX has less shares outstanding
NUTX has more shares outstanding than it did 5 years ago.
The debt/assets ratio for NUTX has been reduced compared to a year ago.
2.2 Solvency
NUTX has an Altman-Z score of 2.00. This is not the best score and indicates that NUTX is in the grey zone with still only limited risk for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 2.00, NUTX is in line with its industry, outperforming 48.54% of the companies in the same industry.
NUTX has a debt to FCF ratio of 4.45. This is a neutral value as NUTX would need 4.45 years to pay back of all of its debts.
The Debt to FCF ratio of NUTX (4.45) is better than 71.84% of its industry peers.
A Debt/Equity ratio of 1.46 is on the high side and indicates that NUTX has dependencies on debt financing.
NUTX has a Debt to Equity ratio of 1.46. This is in the lower half of the industry: NUTX underperforms 70.87% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.46 | ||
| Debt/FCF | 4.45 | ||
| Altman-Z | 2 |
ROIC/WACC4.14
WACC7.38%
2.3 Liquidity
A Current Ratio of 2.27 indicates that NUTX has no problem at all paying its short term obligations.
NUTX has a Current ratio of 2.27. This is in the better half of the industry: NUTX outperforms 76.70% of its industry peers.
A Quick Ratio of 2.26 indicates that NUTX has no problem at all paying its short term obligations.
NUTX's Quick ratio of 2.26 is fine compared to the rest of the industry. NUTX outperforms 77.67% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.27 | ||
| Quick Ratio | 2.26 |
3. Growth
3.1 Past
NUTX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 430.28%, which is quite impressive.
Looking at the last year, NUTX shows a very strong growth in Revenue. The Revenue has grown by 141.25%.
NUTX shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 222.96% yearly.
EPS 1Y (TTM)430.28%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%526.67%
Revenue 1Y (TTM)141.25%
Revenue growth 3Y194.48%
Revenue growth 5Y222.96%
Sales Q2Q%213.98%
3.2 Future
NUTX is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 25.68% yearly.
The Revenue is expected to grow by 64.29% on average over the next years. This is a very strong growth
EPS Next Y-9.22%
EPS Next 2Y25.68%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year157.09%
Revenue Next 2Y64.29%
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
NUTX is valuated cheaply with a Price/Earnings ratio of 7.50.
Based on the Price/Earnings ratio, NUTX is valued cheaply inside the industry as 93.20% of the companies are valued more expensively.
NUTX's Price/Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 26.54.
A Price/Forward Earnings ratio of 6.47 indicates a rather cheap valuation of NUTX.
Based on the Price/Forward Earnings ratio, NUTX is valued cheaply inside the industry as 94.17% of the companies are valued more expensively.
NUTX is valuated cheaply when we compare the Price/Forward Earnings ratio to 35.28, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 7.5 | ||
| Fwd PE | 6.47 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, NUTX is valued cheaply inside the industry as 98.06% of the companies are valued more expensively.
Based on the Price/Free Cash Flow ratio, NUTX is valued cheaply inside the industry as 88.35% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 7.15 | ||
| EV/EBITDA | 3.23 |
4.3 Compensation for Growth
NUTX has a very decent profitability rating, which may justify a higher PE ratio.
NUTX's earnings are expected to grow with 25.68% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y25.68%
EPS Next 3YN/A
5. Dividend
5.1 Amount
NUTX does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
89.23
-4.36 (-4.66%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)
Earnings (Next)
Inst Owners18.53%
Inst Owner Change-4.64%
Ins Owners3.16%
Ins Owner Change0%
Market Cap496.12M
Analysts82.22
Price Target253.3 (183.87%)
Short Float %22.9%
Short Ratio3.33
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly Dividend0.25
Dividend Growth(5Y)N/A
DP19.83%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)4474.63%
Min EPS beat(2)9.6%
Max EPS beat(2)8939.67%
EPS beat(4)3
Avg EPS beat(4)2105.75%
Min EPS beat(4)-602.61%
Max EPS beat(4)8939.67%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)143.87%
Min Revenue beat(2)76.42%
Max Revenue beat(2)211.33%
Revenue beat(4)4
Avg Revenue beat(4)75.65%
Min Revenue beat(4)5.5%
Max Revenue beat(4)211.33%
Revenue beat(8)5
Avg Revenue beat(8)36.33%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)168.98%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-264.53%
EPS NY rev (1m)-26.7%
EPS NY rev (3m)91.07%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)84.37%
Revenue NY rev (1m)0%
Revenue NY rev (3m)90.06%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 7.5 | ||
| Fwd PE | 6.47 | ||
| P/S | 0.79 | ||
| P/FCF | 7.15 | ||
| P/OCF | 6.98 | ||
| P/B | 2.52 | ||
| P/tB | 2.95 | ||
| EV/EBITDA | 3.23 |
EPS(TTM)11.89
EY13.33%
EPS(NY)13.79
Fwd EY15.45%
FCF(TTM)12.49
FCFY14%
OCF(TTM)12.78
OCFY14.32%
SpS112.28
BVpS35.45
TBVpS30.21
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 8.82% | ||
| ROE | 34.08% | ||
| ROCE | 35.61% | ||
| ROIC | 30.54% | ||
| ROICexc | 35.64% | ||
| ROICexgc | 37.81% | ||
| OM | 33.39% | ||
| PM (TTM) | 10.76% | ||
| GM | 48.77% | ||
| FCFM | 11.12% |
ROA(3y)-33.97%
ROA(5y)-688.28%
ROE(3y)-160.63%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y22.83%
GM growth 5Y0.83%
F-Score8
Asset Turnover0.82
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.46 | ||
| Debt/FCF | 4.45 | ||
| Debt/EBITDA | 1.26 | ||
| Cap/Depr | 8.22% | ||
| Cap/Sales | 0.26% | ||
| Interest Coverage | 59.03 | ||
| Cash Conversion | 31.12% | ||
| Profit Quality | 103.36% | ||
| Current Ratio | 2.27 | ||
| Quick Ratio | 2.26 | ||
| Altman-Z | 2 |
F-Score8
WACC7.38%
ROIC/WACC4.14
Cap/Depr(3y)59.19%
Cap/Depr(5y)N/A
Cap/Sales(3y)3.66%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)430.28%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%526.67%
EPS Next Y-9.22%
EPS Next 2Y25.68%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)141.25%
Revenue growth 3Y194.48%
Revenue growth 5Y222.96%
Sales Q2Q%213.98%
Revenue Next Year157.09%
Revenue Next 2Y64.29%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y4652.96%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year1011.2%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y98.21%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y31.51%
OCF growth 3YN/A
OCF growth 5YN/A